Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Res. 2020 Oct 6;80(23):5344–5354. doi: 10.1158/0008-5472.CAN-19-0677

Fig. 2. SEL, ELT, and KOS sensitize newly diagnosed and relapsed/refractory patient MM cells to MEL.

Fig. 2.

Bone marrow mononuclear cells from newly diagnosed (n = 20) and relapsed/refractory (n = 11) patients: (A) newly diagnosed CD138+/light chain+ cells; (B) CD138−/light chain− cells; (C) relapsed/refractory CD138+/light chain+ cells; and (D) relapsed/refractory CD138−/light chain− cells. Patient bone marrow mononuclear cells were isolated and treated with SEL (300 nM) or ELT (300 nM) ± MEL (10 μM) for 20 hours. Cells were fluorescently labeled with antibodies against activated caspase 3, CD138, and light chain antigen (LC) (κ or λ) and analyzed by flow cytometry. Supplemental table S2 shows the last treatments that the relapsed/refractory patients received before the bone marrow aspirate was obtained.